hVIVO (LON:HVO) Posts Earnings Results

hVIVO (LON:HVO) posted its quarterly earnings data on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Trading Down 1.8%

HVO stock traded down GBX 0.11 during midday trading on Wednesday, hitting GBX 5.99. The stock had a trading volume of 2,155,233 shares, compared to its average volume of 2,550,612. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75. The firm has a market cap of £41.24 million, a P/E ratio of -6.89 and a beta of 1.69. The business has a fifty day moving average price of GBX 6.81 and a two-hundred day moving average price of GBX 7.41. hVIVO has a 1-year low of GBX 4.30 and a 1-year high of GBX 11.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.